1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6849A6F341478B209002586B2004A0AB0
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-omnichannel-marketing-mobile-engagement-digital-innovation?opendocument
18
19opendocument
2044.200.122.214
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Digital Technology » Digital Marketing Strategies

Omnichannel Marketing: Mobile Engagement and Digital Innovation

ID: 5681


Features:

9 Info Graphics

21 Data Graphics

330+ Metrics

1 Narratives


Pages/Slides: 37


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Omnichannel Marketing: Mobile Engagement and Digital Innovation”

STUDY OVERVIEW

The acceleration and proliferation of digital marketing has transformed the speed with which patients, physicians, payers, and other customer groups can be engaged across numerous channels. This instant access enables pharma to effectively maintain relationships with these critical stakeholders.

Best Practices, LLC undertook this benchmarking research to examine how leading biopharma companies are adopting an integrated omnichannel marketing strategy by maximizing their digital assets. The study establishes industry benchmarks around mobile engagement and digital health.

The study uses multiple data segments to capture relevant insights for different healthcare players. Segmentations used in the study include:


Total Benchmark Class - 35 respondents
Segmentation by Company Size - Large Pharma (19 respondents) and Small Pharma (15 respondents)
Segmentation by Region - Global (9 respondents) and U.S. Only (10 respondents)
Segmentation by Digital Maturity - Digital Leaders (8 respondents), Digital Majority (17 respondents), and Digital Laggards (10 respondents)

KEY TOPICS

  • Mobile Engagement
  • Digital Health

KEY METRICS
  • How successful has your company been in educating customers, informing treatment decisions, or providing service value via the listed mobile apps and tools?
  • How successful has your company been in supporting digital health via the listed mobile apps, tools and capabilities for patients and physicians?
  • How are you integrating digital health opportunities into digital operations?
  • What ROI have you been able to show for the listed digital activity areas?
  • How has your Digital Marketing group made use of social media over the past year?
  • How valuable are the listed tactics to support the expanded use of electronic health records (EHRs) by physicians?
  • What steps are you undertaking to grow digital engagement with IDNs?
  • What digital marketing strategies have worked best for raising one of your product’s share of voice, particularly in an established market?
  • How significant are each of the listed challenges to the growth and long-term success of your digital marketing function?

SAMPLE KEY FINDINGS
  • Innovative Digital Activities: Data collection of social listening (64%) and patient journey (50%) was the most used form of social media by digital teams.
  • Mobile Engagement and Digital Activities: Companies are successfully hiring new talent to drive digital health innovations. 71% of digital leaders collaborate with industry players to share health data.

METHODOLOGY

Best Practices, LLC engaged 35 executives from 29 leading life sciences companies in this research through a benchmarking survey. Directors and higher management executives represent nearly 80% of the benchmark participants.

Industries Profiled:
Diagnostic; Pharmaceutical; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Clinical Research; Health Care; Communications; Consulting; Laboratories; Marketing


Companies Profiled:
Alere; Almirall; Alnylam Pharmaceuticals; AstraZeneca; Bausch Health; Bayer; Boehringer Ingelheim; CMIC; Daiichi Sankyo; Dentsply Sirona; EMD Serono; Ipsen; Johnson & Johnson; Merck KGaA; Merck Sharp & Dohme; Medtronic; Novartis; NexGen Healthcare Communications; Octapharma; Precision For Value; Roche; Salix Pharmaceutical; Sanofi; Smith & Nephew; Takeda Pharmaceuticals; The Himalaya Drug Company; UCB Pharma; West 53rd St Digital

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.